Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novavax Inc (NVAX)

Novavax Inc (NVAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,340,617
  • Shares Outstanding, K 162,499
  • Annual Sales, $ 682,160 K
  • Annual Income, $ -187,500 K
  • EBIT $ 307 M
  • EBITDA $ 356 M
  • 60-Month Beta 2.58
  • Price/Sales 1.29
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 88.04% (+5.94%)
  • Historical Volatility 85.70%
  • IV Percentile 61%
  • IV Rank 17.27%
  • IV High 257.13% on 01/28/26
  • IV Low 52.73% on 06/30/25
  • Expected Move (DTE 4) 0.68 (8.24%)
  • Put/Call Vol Ratio 0.18
  • Today's Volume 4,762
  • Volume Avg (30-Day) 20,491
  • Put/Call OI Ratio 0.44
  • Today's Open Interest 224,795
  • Open Int (30-Day) 256,274
  • Expected Range 7.57 to 8.93

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.66
  • Number of Estimates 4
  • High Estimate -0.31
  • Low Estimate -1.37
  • Prior Year -0.51
  • Growth Rate Est. (year over year) -29.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.15 +15.38%
on 01/12/26
10.20 -19.12%
on 01/27/26
+0.81 (+10.89%)
since 01/06/26
3-Month
6.20 +33.06%
on 11/20/25
10.20 -19.12%
on 01/27/26
+0.66 (+8.70%)
since 11/06/25
52-Week
5.01 +64.67%
on 04/10/25
10.64 -22.50%
on 08/18/25
-0.02 (-0.24%)
since 02/06/25

Most Recent Stories

More News
3 Cash-Heavy Stocks That Fall Short

3 Cash-Heavy Stocks That Fall Short

AI : 11.65 (+14.78%)
BOX : 24.67 (+1.48%)
NVAX : 8.25 (+4.83%)
3 Healthcare Stocks We Steer Clear Of

3 Healthcare Stocks We Steer Clear Of

NVAX : 8.25 (+4.83%)
AMRX : 14.52 (-1.69%)
DVA : 140.83 (-5.62%)
Why Are Novavax (NVAX) Shares Soaring Today

Why Are Novavax (NVAX) Shares Soaring Today

NVAX : 8.25 (+4.83%)
Novavax Announces Entering into a License Agreement with Pfizer

GAITHERSBURG, Md. , Jan. 20, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has entered into a license agreement with Pfizer for use of Novavax's Matrix-M ® adjuvant. Under the terms of...

NVAX : 8.25 (+4.83%)
2 Growth Stocks with Explosive Upside and 1 That Underwhelm

2 Growth Stocks with Explosive Upside and 1 That Underwhelm

NFLX : 82.20 (+1.64%)
TTMI : 98.58 (+6.48%)
NVAX : 8.25 (+4.83%)
Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference

GAITHERSBURG, Md. , Jan. 7, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the 44 th Annual J.P. Morgan Healthcare Conference.

NVAX : 8.25 (+4.83%)
Q3 Earnings Outperformers: Novavax (NASDAQ:NVAX) And The Rest Of The Therapeutics Stocks

Q3 Earnings Outperformers: Novavax (NASDAQ:NVAX) And The Rest Of The Therapeutics Stocks

NVAX : 8.25 (+4.83%)
Novavax (NVAX) Stock Trades Up, Here Is Why

Novavax (NVAX) Stock Trades Up, Here Is Why

NVAX : 8.25 (+4.83%)
Novavax (NASDAQ:NVAX) Surprises With Q3 CY2025 Sales

Novavax (NASDAQ:NVAX) Surprises With Q3 CY2025 Sales

NVAX : 8.25 (+4.83%)
Novavax to Participate in Jefferies London Healthcare Conference

GAITHERSBURG, Md. , Nov. 12, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the following upcoming investor conference:

NVAX : 8.25 (+4.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company is also developing proprietary immune stimulating saponin-based adjuvants, namely Matrix-M, which already enhanced immune responses and were well-tolerated in multiple...

See More

Key Turning Points

3rd Resistance Point 8.89
2nd Resistance Point 8.60
1st Resistance Point 8.43
Last Price 8.25
1st Support Level 7.96
2nd Support Level 7.67
3rd Support Level 7.49

See More

52-Week High 10.64
Fibonacci 61.8% 8.49
Last Price 8.25
Fibonacci 50% 7.83
Fibonacci 38.2% 7.16
52-Week Low 5.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar